1. Home
  2. CHMI vs SKYE Comparison

CHMI vs SKYE Comparison

Compare CHMI & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cherry Hill Mortgage Investment Corporation

CHMI

Cherry Hill Mortgage Investment Corporation

HOLD

Current Price

$2.48

Market Cap

83.3M

Sector

Real Estate

ML Signal

HOLD

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$1.16

Market Cap

44.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHMI
SKYE
Founded
2012
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.3M
44.9M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
CHMI
SKYE
Price
$2.48
$1.16
Analyst Decision
Hold
Strong Buy
Analyst Count
3
5
Target Price
$2.75
$14.75
AVG Volume (30 Days)
283.5K
285.3K
Earning Date
11-06-2025
11-10-2025
Dividend Yield
16.13%
N/A
EPS Growth
N/A
N/A
EPS
0.02
N/A
Revenue
$40,202,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$52.49
N/A
P/E Ratio
$132.37
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.17
$1.11
52 Week High
$3.68
$5.75

Technical Indicators

Market Signals
Indicator
CHMI
SKYE
Relative Strength Index (RSI) 61.47 35.09
Support Level $2.20 $1.10
Resistance Level $2.42 $1.38
Average True Range (ATR) 0.09 0.10
MACD 0.03 0.02
Stochastic Oscillator 96.97 11.90

Price Performance

Historical Comparison
CHMI
SKYE

About CHMI Cherry Hill Mortgage Investment Corporation

Cherry Hill Mortgage Investment Corp operates as a real estate investment trust in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, primarily through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: